Ionis Pharmaceuticals (NASDAQ:IONS) Given New $125.00 Price Target at HC Wainwright

Ionis Pharmaceuticals (NASDAQ:IONS) had its target price cut by analysts at HC Wainwright from $130.00 to $125.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 108.05% from the stock’s current price.

A number of other research analysts have also weighed in on the company. Raymond James Financial set a $87.00 price objective on Ionis Pharmaceuticals in a report on Thursday. TD Cowen reaffirmed a “buy” rating and set a $108.00 target price on shares of Ionis Pharmaceuticals in a report on Monday, June 15th. Jefferies Financial Group dropped their target price on Ionis Pharmaceuticals from $113.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday. Royal Bank Of Canada increased their price target on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, April 30th. Finally, Canaccord Genuity Group reduced their price target on shares of Ionis Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a research report on Friday. Eighteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $96.80.

Ionis Pharmaceuticals Stock Performance

Shares of NASDAQ:IONS traded down $4.19 on Friday, hitting $60.08. 2,147,609 shares of the company were exchanged, compared to its average volume of 2,220,887. The firm has a market capitalization of $9.93 billion, a P/E ratio of -29.06 and a beta of 0.36. The company has a current ratio of 4.10, a quick ratio of 4.09 and a debt-to-equity ratio of 2.75. Ionis Pharmaceuticals has a 1-year low of $40.03 and a 1-year high of $86.74. The stock’s 50 day moving average price is $76.12 and its 200 day moving average price is $77.41.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.29. The firm had revenue of $246.09 million for the quarter, compared to the consensus estimate of $195.56 million. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The firm’s revenue was up 86.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.93) EPS. Sell-side analysts predict that Ionis Pharmaceuticals will post -3.69 EPS for the current year.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, EVP Eugene Schneider sold 26,000 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $81.05, for a total value of $2,107,300.00. Following the completion of the transaction, the executive vice president directly owned 77,114 shares of the company’s stock, valued at approximately $6,250,089.70. The trade was a 25.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP C Frank Bennett sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $85.46, for a total value of $1,281,900.00. Following the completion of the sale, the executive vice president owned 75,018 shares in the company, valued at approximately $6,411,038.28. This represents a 16.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 244,038 shares of company stock worth $19,139,399. 1.81% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Brown Brothers Harriman & Co. purchased a new stake in Ionis Pharmaceuticals during the 4th quarter worth approximately $27,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Ionis Pharmaceuticals in the first quarter worth approximately $30,000. Quarry LP acquired a new stake in shares of Ionis Pharmaceuticals in the third quarter worth approximately $38,000. Johnson Financial Group Inc. purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter worth approximately $44,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $47,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Ionis Pharmaceuticals News Summary

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Negative Sentiment: Ionis and AstraZeneca reported that the Phase 3 CARDIO-TTRansform trial of eplontersen in ATTR-CM did not meet its primary efficacy endpoint, a significant clinical disappointment that could hurt confidence in the drug’s commercial outlook. Article Title
• Negative Sentiment: Reuters reported that AstraZeneca-Ionis’ Wainua failed to reduce cardiovascular deaths and recurring heart problems in a late-stage study, reinforcing concerns about the company’s cardiovascular franchise. Article Title
• Negative Sentiment: Unusually large put option buying suggests traders are positioning for more downside after the trial failure.
• Negative Sentiment: Recent insider selling by EVP Holly B. Kordasiewicz and Director Allene M. Diaz may add to near-term investor caution, even though the trades were made under pre-arranged 10b5-1 plans.
• Neutral Sentiment: Needham lowered its price target on Ionis Pharmaceuticals from $105 to $86 while maintaining a Buy rating, and Canaccord Genuity cut its target from $110 to $95 but also kept a Buy rating, signaling reduced expectations but continued long-term optimism. Article Title
• Neutral Sentiment: The company also issued FY 2026 revenue guidance of $875 million to $900 million, which appears broadly in line with consensus and may help offset some of the trial-related selling pressure.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.